Search Results
Your search for ,WHo matches 21057 pages
Showing 17451 - 17500SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Surgery in Stage I/II Invasive Breast Cancer
The Society of Surgical Oncology (SSO) and American Society for Radiation Oncology (ASTRO) formed a multidisciplinary expert panel in 2013 to examine the relationship between surgical margin width and ipsilateral breast tumor recurrence and develop guidelines on margins for breast-conserving...
Identifying One Main Provider and Involving Oncology Specialist Are Key to High-Quality Rating for Follow-up Care
Long-term cancer survivors are more likely to rate their follow-up care as high-quality when one main provider is identified and an oncology specialist is involved, according to results of a population-based cross-sectional study among adult survivors of breast, prostate, colorectal, endometrial,...
Brentuximab Vedotin Shows Antitumor Activity in Patients With Relapsed Peripheral T-Cell Lymphoma
In a phase II study, the 34 evaluable patients with peripheral T-cell lymphomas who received brentuximab vedotin (Adcetris) had an overall response rate of 41%, including an overall response rate of 54% among the 13 patients with angioimmunoblastic T-cell lymphoma. The median progression-free...
Desensitization Protocols May Allow Reintroduction of Chemotherapeutic Agents After Hypersensitivity Reactions
Hypersensitivity reactions to chemotherapeutic agents used to treat ovarian cancer are “increasingly common and can greatly limit their use,” according to an article published in the Journal of the National Comprehensive Cancer Network. “Drug desensitization has emerged as a safe and effective way...
Ongoing Clinical Trials Actively Recruiting Patients With Hodgkin Lymphomas
The information in this Clinical Trials Resource Guide includes details of actively recruiting clinical studies of patients with Hodgkin lymphomas, including patients with human immunodeficiency virus–associated and Epstein-Barr virus–positive Hodgkin lymphoma. Two of the studies are also...
American Association for Cancer Research Inaugurates 2014 Class of Fellows
The American Association for Cancer Research (AACR) inducted the 2014 class of elected Fellows of the AACR Academy at the Association’s Annual Meeting, held recently in San Diego. The AACR Academy is an entity within the AACR that recognizes those individuals who have made exceptional contributions ...
Bringing the Humanistic Approach to Palliative Care: From Diagnosis and Throughout Disease Course
For much of her career in oncology, Teresa A. Gilewski, MD, has sought to bridge the science of medicine with the humanistic aspect of care. She has created the Art of Medicine lecture series at Memorial Sloan Kettering Cancer Center in New York, where she is a medical oncologist on the Breast...
Expert Point of View: Joyce F. Liu, MD, MPH, of Dana-Farber Cancer Institute, and Stephen A. Cannistra, MD
In an editorial accompanying publication of the AURELIA study results, Joyce F. Liu, MD, MPH, of Dana-Farber Cancer Institute, and Stephen A. Cannistra, MD, of Beth Israel Deaconess Medical Center, Boston, considered the implications of the benefits observed in the trial and limitations in...
AURELIA Trial: Adding Bevacizumab to Chemotherapy Improves Outcomes in Platinum-Resistant Recurrent Ovarian Cancer
Single-agent chemotherapy is standard in platinum-resistant ovarian cancer. In the open-label phase III AURELIA trial reported in the Journal of Clinical Oncology, Eric Pujade-Lauraine, MD, PhD, of Université Paris Descartes, and colleagues found that the addition of bevacizumab (Avastin) to...
ASCO Rolls Out Support for Changes in Maintenance of Certification Requirements
Big changes came to the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program requirements in 2014. As of January 1, all diplomates, including “grandfathers” (or those certified before 1990 who are “board-certified for life”), must actively participate in MOC...
Enhance Your ASCO Annual Meeting Experience With Attendee Resources
At the end of the month, more than 25,000 oncology professionals from around the world will meet in Chicago for the 2014 ASCO Annual Meeting. Will you be joining this global community? As you’re beginning to consider what to pack for your trip, keep in mind that you have a host of electronic...
Expert Point of View: Thomas J. Herzog, MD
PARP inhibitors are a very promising strategy that moves the treatment of ovarian cancer into the era of personalized medicine,” said Thomas J. Herzog, MD, Director of Gynecologic Oncology at Columbia University Medical Center, New York. “We now have a biomarker for identifying who will benefit...
Preliminary Study Suggests Veliparib May Be Effective in Resistant, BRCA-Mutated Ovarian Cancers
Veliparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, appears to be of value in treating women with BRCA-mutated gynecologic cancers that are resistant to other therapies. These preliminary findings of a phase II study support the concept that BRCA-associated ovarian cancers are...
Expert Point of View: David M. O’Malley, MD
David M. O’Malley, MD, Assistant Professor at The James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University College of Medicine, Columbus, commented on the abstract presented by Ward et al at the Annual Meeting on Women’s Cancer. “Dr. Ward and colleagues report further...
Bariatric Surgery Reduces Risk of Uterine Cancer in Obese Women
Bariatric surgery for weight loss appears to protect obese women from developing uterine cancer, according to a large retrospective study presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, held March 22–25 in Tampa, Florida. The study found that obese women who ...
High-Risk Uterine Cancers Found in BRCA1 Mutation Carriers Who Had Preventive Oophorectomy but Not Hysterectomy
Prophylactic surgery to remove the ovaries and fallopian tubes is advised for women who carry BRCA mutations to reduce the risk of breast and ovarian cancer. This procedure, referred to as risk-reducing salpingo-oophorectomy, typically does not require a hysterectomy. However, a new study presented ...
Expert Point of View: William Cliby, MD
When asked to comment on the study presented by Lin et al at the Annual Meeting on Women’s Cancer, William Cliby, MD, Chair, Division of Surgery, The Mayo Clinic, Rochester, Minnesota, said, “This study is important because of its size and the utilization of the National Cancer Data Base—the...
Gynecologic Cancer Treatment at High-Volume Centers May Be Lifesaving
Women with gynecologic cancers who are treated at hospitals that frequently manage these conditions appear to live significantly longer than those who receive their care at lower-volume centers, according to a large study presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on...
FDA Approves Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia
The U.S. Food and Drug Administration (FDA) has approved ofatumumab (Arzerra) injection in combination with chlorambucil (Leukeran) for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate. The...
SIDEBAR: Should You Treat Smoldering Multiple Myeloma?
A recent article in The New England Journal of Medicine has provoked conversation about the management of smoldering multiple myeloma.1 At the recent National Comprehensive Cancer Network (NCCN) Annual Conference, Kenneth C. Anderson, MD, of Dana-Farber Cancer Institute, Boston, shared his thoughts ...
Promising Compounds in Development for Multiple Myeloma
The term “novel agents” has been used for the past decade to describe proteasome inhibitors and immunomodulatory drugs that are now conventionally used for multiple myeloma. However, even newer agents in development will be considered truly novel when they hit the market, as they represent new...
Surgery Plus Radiation Offers Mixed Results in Soft-Tissue Sarcoma
Adjuvant radiation following surgery for soft-tissue sarcomas of the extremities did not lead to a survival benefit and seemed to be associated with some degree of long-term limb complications, according to a presentation at the 2014 Society of Surgical Oncology (SSO) Cancer Symposium in Phoenix.1...
Patients With Thin Melanoma Benefit From Sentinel Lymph Node Biopsy
Sentinel node status is “the most powerful predictor” of melanoma-specific survival in patients with thin melanoma, according to a presentation at the 2014 Society of Surgical Oncology (SSO) Cancer Symposium in Phoenix.1 As a result, sentinel lymph node biopsy should be considered in patients with...
PD-L1 Studied as Biomarker for Anti–PD-1 Immunotherapy
The anti–PD-1 inhibitor MK-3475 (formerly lambrolizumab) is in late-stage trials for advanced melanoma and is also being studied in other malignancies, including non–small cell lung cancer (NSCLC). An important aspect of Merck’s development program for MK-3475, as well as for other anti–PD-1 agents ...
LY2835219 Shows Strong Single-Agent Activity in Preliminary Study in Metastatic Breast Cancer
Inhibitors of cyclin-dependent kinase (CDK) 4/6 are getting attention as a novel approach for the treatment of breast cancer. At the 2014 American Association for Cancer Research (AACR) Annual Meeting, two presentations focused on these new agents. One was a phase II study of Pfizer’s compound...
Maintenance Therapy in Multiple Myeloma
In 2012, three randomized placebo-controlled trials reported a significant prolongation of progression-free survival with lenalidomide (Revlimid) as maintenance therapy for multiple myeloma.1-3 Two of these trials tested lenalidomide maintenance after stem cell transplantation, and one investigated ...
Collaborative Exchange: The Expanded Access Program and Uridine Triacetate
The panel discussed the various aspects of obtaining a drug such as uridine triacetate through the expanded access program. Ms. Vogel: The expanded access program allows companies to provide patients access to their medicines while the drugs are still in preapproval process, but it is strictly...
Questions Answered About Uridine Triacetate
Q. What is uridine triacetate? A. It is an investigational, orally active prodrug of uridine currently under development as an antidote to overexposure of fluorouracil (5-FU). Although not yet approved by the U.S. Food and Drug Administration, it has been shown to be effective in treating patients...
CE Activity Instructions
CE is available on May 1, 2014 and expires on May 1, 2015. A continuing education activity for physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other allied health professionals specializing in the field of oncology. This activity is supported by an unrestricted...
Genitourinary Toxicity More Likely With Stereotactic Body Radiotherapy Than With Intensity-Modulated Radiotherapy
A retrospective analysis of patients with prostate cancer receiving primary treatment with either stereotactic body radiation therapy or intensity-modulated radiation therapy found that those receiving stereotactic body radiotherapy had greater rates of genitourinary toxicity during 2-year...
Don’t Always Expect Questions From Patients About Prognosis
Although most patients want to know about the potential outcome of their disease and whether treatment is likely to have a significant impact on it, the information needs of patients and how best to fulfill those needs are very variable, Walter F. Baile, MD, told The ASCO Post. Dr. Baile is...
Breaking Bad News Badly Can Add to Upset
When the prognosis is poor, breaking the bad news badly can exacerbate the distress experienced by cancer patients and their families. A lack of sensitivity to patient and family emotions and not being attuned to how individual patients would prefer to be informed about their prognoses can result...
ASCO Cofounder Jane Cooke Wright, MD, Defied Racial/Gender Barriers and Helped Usher in the Modern Age of Chemotherapy
When Jane Cooke Wright, MD, met with six other oncologists at the Edgewater Beach Hotel in Chicago on April 9, 1964, to discuss the creation of American Society of Clinical Oncology, the first medical society dedicated to bringing patient-oriented issues to clinical oncology, the Civil Rights Act...
ASCO’s Visionary Founders
On April 9, 1964, seven physicians—Jane Cooke Wright, MD, FASCO; Arnoldus Goudsmit, MD, PhD; Fred J. Ansfield, MD, FASCO; Harry F. Bisel, MD, FASCO; Herman H. Freckman, MD, FASCO; Robert W. Talley, MD, FASCO; and William Wilson, MD, FASCO—met for lunch at the Edgewater Beach Hotel in Chicago. They...
The Camaraderie of ASCO
Oncologists are occupied with an unusual kind of medicine, and, as a result, we are exposed to enormous personal stress and strain, because patients we care for are profoundly sick with potentially fatal diseases. As a group, we deal with the possible mortality of those for whom we are responsible...
Multidisciplinary Interactions
As my Presidency gradually fades into the past, it is sobering to reminisce on how exciting it was. ASCO is a great organization with an amazing staff and a solid mission. Chairing the Board meetings was clearly a highlight of my Presidency because of the vast talent and collective wisdom that is...
SIDEBAR: FDA-Approved Drugs to Use as Single Agents or in Combination Chemotherapy
2014 Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic NSCLC with disease progression on or who are intolerant to crizotinib; mercaptopurine as a 20 mg/mL oral suspension for the treatment of acute lymphoblastic leukemia as part of a combination...
Building Bridges to Conquer Cancer
One of the pleasures during my year as President was the ability to bring personal and professional passions and a sense of what really matters into focus for the work of our membership. My Presidential theme, Building Bridges to Conquer Cancer, reflected my particular interest in outreach to...
Celebrating ASCO's History, 1964-2014
The last 50 years have been marked by significant advances in cancer research and in more effective therapy for patients. Once viewed as a largely untreatable, fatal disease, today a number of cancers are being converted into chronic diseases that can be managed for long periods of time. The result ...
The Leukemia & Lymphoma Society Surpasses $1 Billion Investment in Blood Cancer Research
The Leukemia & Lymphoma Society (LLS) has announced that it has passed the $1 billion mark in research investment, a significant milestone in the cancer research landscape as the Society continues its 65-year pursuit of advancing breakthrough therapies, finding cures, and ensuring access to...
An Oncologic Surgeon Discusses the Pros and Cons of Pursuing a Business Degree
Is pursuing a Master of Business Administration (MBA) degree a good idea for ambitious surgical oncologists who want to advance their careers? The ASCO Post recently spoke with Martin J. Heslin, MD, MSHA, Chief, Section of Surgical Oncology, University of Alabama at Birmingham (UAB) Medical Center, ...
A Vision of Independent Clinical Research in South America
Clinical research is vital for the development and improvement of methods designed to prevent and treat cancer. The majority of clinical trials take place in the developed world through sponsored pharmaceutical research companies.1 The corresponding lack of research in developing countries results...
Ramucirumab for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
On April 21, 2014, ramucirumab (Cyramza) was approved for use as a single agent in the treatment of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing...
May Is National Skin Cancer Awareness Month
According to the Skin Cancer Foundation, more than 3.5 million cases of skin cancer are diagnosed each year, with the incidences of skin cancer outnumbering all cases of breast, colon, lung, and prostate cancers combined. Of the three most common types of skin cancer—basal cell carcinoma, squamous...
Irving Bone Marrow Transplant Unit Opens at NewYork-Presbyterian/Columbia
New York-Presbyterian/Columbia University Medical Center has opened the Irving Bone Marrow Transplant Unit, a state-of-the-art facility for comprehensive bone marrow transplant (BMT) care. The new unit features 18 inpatient rooms, a high-tech nurses station for individual patient monitoring, and a...
Bert Howard O’Neil, MD, Joins Indiana University Simon Cancer Center
Bert Howard O’Neil, MD, has been named the inaugural Joseph W. and Jackie J. Cusick Professor of Oncology and a Professor of Medicine at the Indiana University (IU) School of Medicine, in Indianapolis. He is also the Phase I Director and Director of the Gastrointestinal Cancer Research Program at...
Personalizing Outreach to Address Asian Cancer Health Disparities
In an effort to reduce cancer health disparities among Asian Americans, UC Davis Comprehensive Cancer Center now offers individual, in-language education and culturally sensitive materials for every Asian American cancer patient. New brochures and 5-minute videos were debuted during the National...
Improving Quality of Life in Cancer Survivors
The number of cancer survivors has been steadily increasing in recent years. According to the Ministry of Health National Cancer Registry, in 2010 there were 254,000 cancer survivors in Israel (3.3% of the population) compared with 15,700 (0.4% of the population, P < .005) in 1975.1 Forty years...
Elevated Morbidity/Mortality Risks for Childhood Cancer Survivors Further Increase After Fourth Decade
An analysis of the first generation of childhood cancer survivors, who are now aging into their fourth and fifth decades, shows further increases in the survivors’ morbidity and mortality risks. “By age 50 years, more than half of survivors have experienced a severe, disabling, or life-threatening...
Ongoing Clinical Trials Actively Recruiting Patients With Ovarian or Cervical Cancers
The information contained in this Clinical Trials Resource Guide includes details of actively recruiting clinical studies of patients with gynecologic and breast cancers. It also includes the Family Caregiver Palliative Care Intervention study, which is investigating interventions to support...
